Some cancer cells dodge immune attacks by staying on the move, preventing complete engulfment. Instead, the body’s defensive cells manage only to nibble at the edges. Scientists are observing how this behavior might shape the future of cancer research and treatment.
Imviva Biotech has revealed promising new data for its allogeneic CAR-T cell therapies, CTD402 and CTA311, at the 67th American Society of Hematology Annual Meeting. Early clinical findings suggest significant progress toward treating T-cell and B-cell malignancies, as well as severe aplastic anemia, through innovative approaches that may offer enhanced efficacy and widened patient access.
Doctors and researchers have long recognized that our immune system has the potential to fight cancer. Recent breakthroughs have finally allowed that principle to evolve into powerful, immune-based therapies that bring renewed hope.
Researchers at The University of Texas MD Anderson Cancer Center have identified seven distinct cellular environments within diffuse large B-cell lymphoma (DLBCL) tumors. These findings point to new avenues for developing therapies that harness the body’s own immune powers to fight cancer.
Researchers have discovered a novel way to retrain neutrophils—the body’s first responders—to directly attack aggressive breast cancer cells, offering new hope to patients unresponsive to current immunotherapies.
Promising advances in immunotherapy may allow some cancer patients to bypass chemotherapy, radiation, and surgery. New clinical trial findings reported by Dr. Jon LaPook suggest a groundbreaking shift in cancer treatment, offering renewed hope to many.
